DS04 - Vie, santé et bien-être

T follicular helper cell in atopic march: innate control and pathogenic role – Tfh-Atopy

Submission summary

Atopic diseases, including atopic dermatitis (AD) and asthma are closely related allergic diseases, sharing common features of “atopy”, with IgE production and type 2 allergic inflammation. Affected individuals often experience the progression from AD to asthma, known as the “atopic march”. Allergen sensitization, which develops through barrier-defective skin in AD individuals and generates T and B cell memory, is a critical step in the onset of the “atopic march”, but its mechanisms remain poorly understood. Our project aims to combine studies from mouse to human, to elucidate the pathogenic role of a new CD4 helper cell subset, T follicular helper (Tfh) cells, in skin allergen sensitization and in the atopic march, and to further explore cellular and molecular mechanisms in Tfh cell differentiation and regulations. Results are expected to reveal Tfh cell as a critical piece of the “atopic march” puzzle, and to identify potential targets of Tfh signaling for developing preventative/therapeutic strategies for atopic diseases.

Project coordination

Mei LI (Institut de génétique et de biologie moléculaire et cellulaire)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

IGBMC Institut de génétique et de biologie moléculaire et cellulaire
INSERM DR PARIS 5 Institut National de la Santé et de la Recherche Médicale, Délégation Régionale Paris 5
INSERM Institut Curie / INSERM Immunity and Cancer U932
U976 U976 équipe 9 Immunologie Systémique Humaine et réseaux inflammatoire

Help of the ANR 468,953 euros
Beginning and duration of the scientific project: September 2017 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter